<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>Libby&#039;s H*O*P*E*</title>
	<atom:link href="http://healthinfoispower.wordpress.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://healthinfoispower.wordpress.com</link>
	<description>*Helping*Ovarian Cancer Survivors*Persevere Through*Education</description>
	<lastBuildDate>Thu, 12 Nov 2009 00:45:53 +0000</lastBuildDate>
	<generator>http://wordpress.com/</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<cloud domain='healthinfoispower.wordpress.com' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://www.gravatar.com/blavatar/e45e223349a1a9906dc639d47d41ea4c?s=96&#038;d=http://s.wordpress.com/i/buttonw-com.png</url>
		<title>Libby&#039;s H*O*P*E*</title>
		<link>http://healthinfoispower.wordpress.com</link>
	</image>
			<item>
		<title>UCLA Researchers Significantly Inhibit Growth of Ovarian Cancer Cell Lines With FDA-Approved Leukemia Drug Dasatinib (Sprycel®)</title>
		<link>http://healthinfoispower.wordpress.com/2009/11/11/ucla-researchers-significantly-inhibit-growth-of-ovarian-cancer-cell-lines-with-fda-approved-leukemia-drug-dasatinib-sprycel%c2%ae/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/11/11/ucla-researchers-significantly-inhibit-growth-of-ovarian-cancer-cell-lines-with-fda-approved-leukemia-drug-dasatinib-sprycel%c2%ae/#comments</comments>
		<pubDate>Thu, 12 Nov 2009 00:45:53 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Biomarker]]></category>
		<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Discoveries]]></category>
		<category><![CDATA[Medical Study Results]]></category>
		<category><![CDATA[Molecular Diagnostics]]></category>
		<category><![CDATA[Novel Therapies]]></category>
		<category><![CDATA[Preclinical Testing]]></category>
		<category><![CDATA[targeted therapies]]></category>
		<category><![CDATA[acute lymphoblastic leukemia]]></category>
		<category><![CDATA[annexin]]></category>
		<category><![CDATA[British Journal of Cancer]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[caveolin]]></category>
		<category><![CDATA[chronic myeloid leukemia]]></category>
		<category><![CDATA[clear cell ovarian cancer]]></category>
		<category><![CDATA[dasatinib]]></category>
		<category><![CDATA[Dennis J. Slamon M.D. Ph.D.]]></category>
		<category><![CDATA[endometrioid ovarian cancer]]></category>
		<category><![CDATA[Eph receptors]]></category>
		<category><![CDATA[EphA2]]></category>
		<category><![CDATA[ephrins]]></category>
		<category><![CDATA[focal adhesion kinase]]></category>
		<category><![CDATA[gene expression study]]></category>
		<category><![CDATA[Gottfried E. Konecny M.D.]]></category>
		<category><![CDATA[Harvard Medical School]]></category>
		<category><![CDATA[HER-2]]></category>
		<category><![CDATA[IGFBP2]]></category>
		<category><![CDATA[Jonsson Comprehensive Cancer Ctr.]]></category>
		<category><![CDATA[Lyn]]></category>
		<category><![CDATA[Mayo Clinic]]></category>
		<category><![CDATA[moesin]]></category>
		<category><![CDATA[molecular markers]]></category>
		<category><![CDATA[mucinous ovarian cancer]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[preclinical test results]]></category>
		<category><![CDATA[serous ovarian cancer]]></category>
		<category><![CDATA[Sprycel]]></category>
		<category><![CDATA[Src dependent ovarian cancer]]></category>
		<category><![CDATA[Src family kinase]]></category>
		<category><![CDATA[STAT3]]></category>
		<category><![CDATA[Taxol]]></category>
		<category><![CDATA[Taxotere]]></category>
		<category><![CDATA[tyrosine kinases]]></category>
		<category><![CDATA[U.S. Food & Drug Administration]]></category>
		<category><![CDATA[UCLA]]></category>
		<category><![CDATA[undifferentiated ovarian cancer]]></category>
		<category><![CDATA[uPA]]></category>
		<category><![CDATA[VEGF]]></category>
		<category><![CDATA[Yes]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3259</guid>
		<description><![CDATA[
The drug dasatinib (Sprycel®), approved for use by the U.S. Food and Drug Administration in patients with specific types of leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, say UCLA researchers in the November 10th issue of the British Journal of Cancer. The drug, when paired with [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3259&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/11/11/ucla-researchers-significantly-inhibit-growth-of-ovarian-cancer-cell-lines-with-fda-approved-leukemia-drug-dasatinib-sprycel%c2%ae/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/11/slamon1.jpg" medium="image">
			<media:title type="html">Dennis Slamon, M.D. Ph.D.</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/11/konecny.jpg" medium="image">
			<media:title type="html">Gottfried E. Konecny, M.D.</media:title>
		</media:content>
	</item>
		<item>
		<title>Æterna Zentaris&#8217; LHRH-Receptor Targeted Therapy AEZS-108 Produces Positive Preliminary Results in Advanced Stage Ovarian Cancer</title>
		<link>http://healthinfoispower.wordpress.com/2009/11/04/%c3%a6terna-zentaris-lhrh-receptor-targeted-therapy-aezs-108-produces-positive-preliminary-results-in-advanced-stage-ovarian-cancer/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/11/04/%c3%a6terna-zentaris-lhrh-receptor-targeted-therapy-aezs-108-produces-positive-preliminary-results-in-advanced-stage-ovarian-cancer/#comments</comments>
		<pubDate>Wed, 04 Nov 2009 20:39:09 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Biological Therapies]]></category>
		<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Clinical Trial Results]]></category>
		<category><![CDATA[Novel Therapies]]></category>
		<category><![CDATA[Pipeline Drugs]]></category>
		<category><![CDATA[AEterna Zentaris]]></category>
		<category><![CDATA[AEZS-108]]></category>
		<category><![CDATA[AGO-GYN5]]></category>
		<category><![CDATA[American Society of Clinical Oncology]]></category>
		<category><![CDATA[AN-152]]></category>
		<category><![CDATA[cytotoxic peptide conjugate]]></category>
		<category><![CDATA[doxorubicin]]></category>
		<category><![CDATA[endometrial cancer]]></category>
		<category><![CDATA[Gunter Emons M.D.]]></category>
		<category><![CDATA[Gynecologic Cancer InterGroup]]></category>
		<category><![CDATA[Gynecological Oncology Working Group]]></category>
		<category><![CDATA[Juergen Engel Ph.D.]]></category>
		<category><![CDATA[LHRH receptors]]></category>
		<category><![CDATA[LHRH-receptor positive ovarian cancer]]></category>
		<category><![CDATA[luteinizing hormone-releasing hormone]]></category>
		<category><![CDATA[NCT00569257]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[RECIST criteria]]></category>
		<category><![CDATA[Univ. of Gottingen]]></category>
		<category><![CDATA[ZEN-008]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3233</guid>
		<description><![CDATA[
Preliminary Phase II clinical study evaluation shows that primary efficacy endpoint has been met for patients with advanced-stage, platinum-resistant, taxane-pretreated ovarian cancer who were treated with the targeted therapy AEZS-108.


Æterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase II study with its [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3233&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/11/04/%c3%a6terna-zentaris-lhrh-receptor-targeted-therapy-aezs-108-produces-positive-preliminary-results-in-advanced-stage-ovarian-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/11/engel.jpg" medium="image">
			<media:title type="html">Juergen Engel, Ph.D., President &#38; CEO, AEterna Zentaris</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/11/aezs-108.jpg" medium="image">
			<media:title type="html">AEZS-108 Mechanism of Action</media:title>
		</media:content>
	</item>
		<item>
		<title>Unusual Metals May Forge New Ovarian &amp; Colon Cancer Drugs</title>
		<link>http://healthinfoispower.wordpress.com/2009/11/01/unusual-metals-may-forge-new-ovarian-colon-cancer-drugs/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/11/01/unusual-metals-may-forge-new-ovarian-colon-cancer-drugs/#comments</comments>
		<pubDate>Mon, 02 Nov 2009 02:57:13 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Novel Therapies]]></category>
		<category><![CDATA[Ovarian Cancer Studies]]></category>
		<category><![CDATA[Preclinical Testing]]></category>
		<category><![CDATA[apoptosis]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[Engineering & Physical Sciences Research Council]]></category>
		<category><![CDATA[Journal of Medicinal Chemistry]]></category>
		<category><![CDATA[medicinal chemistry]]></category>
		<category><![CDATA[osmium]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[Patrick McGowan]]></category>
		<category><![CDATA[Prof. Peter Sadler]]></category>
		<category><![CDATA[ruthenium]]></category>
		<category><![CDATA[Univ. of Leeds]]></category>
		<category><![CDATA[Univ. of Warwick]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3217</guid>
		<description><![CDATA[
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3217&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/11/01/unusual-metals-may-forge-new-ovarian-colon-cancer-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/11/cowen.jpg?w=300" medium="image">
			<media:title type="html">Dr. Peter Sadler </media:title>
		</media:content>
	</item>
		<item>
		<title>U.S. Ovarian Cancer Research Funding Slashed In Half &#8212; Take Action &amp; Call Your U.S. Congressman &amp; Senators Today!</title>
		<link>http://healthinfoispower.wordpress.com/2009/10/23/ovarian-cancer-research-funding-slashed-in-half-take-action-call-your-u-s-congressman-senators-today/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/10/23/ovarian-cancer-research-funding-slashed-in-half-take-action-call-your-u-s-congressman-senators-today/#comments</comments>
		<pubDate>Fri, 23 Oct 2009 17:31:11 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Advocacy]]></category>
		<category><![CDATA[Department of Defense]]></category>
		<category><![CDATA[National Ovarian Cancer Alliance]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[Ovarian Cancer Research Program]]></category>
		<category><![CDATA[research funding]]></category>
		<category><![CDATA[U.S. House of Representatives]]></category>
		<category><![CDATA[U.S. Senate]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3203</guid>
		<description><![CDATA[As a result of a recent  U.S. Senate mark-up, the funding for the Department of Defense Ovarian Cancer Research Program (DOD OCRP) has been slashed in half from $20 million to $10 million. Research conducted under the DOD OCRP program is critical because it is solely dedicated to ovarian cancer. &#8230; Please help us [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3203&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/10/23/ovarian-cancer-research-funding-slashed-in-half-take-action-call-your-u-s-congressman-senators-today/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/10/rosie_the_riveter.jpg?w=231" medium="image">
			<media:title type="html">Rosie The riveter</media:title>
		</media:content>
	</item>
		<item>
		<title>Endocyte&#8217;s EC145 Produces Significant Anti-Tumor Activity In Advanced Stage Chemoresistant Ovarian Cancer Patients</title>
		<link>http://healthinfoispower.wordpress.com/2009/10/21/endocytes-ec145-produces-significant-anti-tumor-activity-in-advanced-stage-chemoresistant-ovarian-cancer-patients/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/10/21/endocytes-ec145-produces-significant-anti-tumor-activity-in-advanced-stage-chemoresistant-ovarian-cancer-patients/#comments</comments>
		<pubDate>Thu, 22 Oct 2009 05:00:40 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Biological Therapies]]></category>
		<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Clinical Trial Results]]></category>
		<category><![CDATA[Novel Therapies]]></category>
		<category><![CDATA[Pipeline Drugs]]></category>
		<category><![CDATA[99mTc-EC20]]></category>
		<category><![CDATA[BMS753493]]></category>
		<category><![CDATA[Caelyx]]></category>
		<category><![CDATA[Doxil]]></category>
		<category><![CDATA[Drug Guidance System]]></category>
		<category><![CDATA[EC0225]]></category>
		<category><![CDATA[EC0489]]></category>
		<category><![CDATA[EC145]]></category>
		<category><![CDATA[EC17]]></category>
		<category><![CDATA[EC20]]></category>
		<category><![CDATA[Endocyte]]></category>
		<category><![CDATA[European Society of Gynaecologic Oncology]]></category>
		<category><![CDATA[folate receptors]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[platinum-resistant]]></category>
		<category><![CDATA[PRECEDENT clinical trial]]></category>
		<category><![CDATA[RECIST]]></category>
		<category><![CDATA[Richard Messmann M.D.]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3178</guid>
		<description><![CDATA[Endocyte, Inc., &#8230;  presented data from a Phase 2a clinical trial for EC145, &#8230; In 49 women with advanced-stage ovarian cancer, EC145 was shown to have anti-tumor activity in a significant percentage of participants in the trial. &#8230;[T]he overall disease control rate, defined as stable disease, partial or complete response to therapy, was 40.8 [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3178&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/10/21/endocytes-ec145-produces-significant-anti-tumor-activity-in-advanced-stage-chemoresistant-ovarian-cancer-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/10/ec20rev.jpg?w=300" medium="image">
			<media:title type="html">EC20 Imaging Results</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/10/precedenttrial.jpg" medium="image">
			<media:title type="html">EC145 PRECEDENT Clinical Trial</media:title>
		</media:content>
	</item>
		<item>
		<title>Modified Chemo Regime Increases Survival In Advanced Ovarian Cancer Patients But Adds Toxicity</title>
		<link>http://healthinfoispower.wordpress.com/2009/09/24/modified-chemo-regime-increases-survival-in-advanced-ovarian-cancer-patients-but-adds-toxicity/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/09/24/modified-chemo-regime-increases-survival-in-advanced-ovarian-cancer-patients-but-adds-toxicity/#comments</comments>
		<pubDate>Thu, 24 Sep 2009 20:44:57 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Clinical Trial Results]]></category>
		<category><![CDATA[Novel Therapies]]></category>
		<category><![CDATA[Arizona Cancer Center]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[dose dense chemotherapy]]></category>
		<category><![CDATA[dose intense chemotherapy]]></category>
		<category><![CDATA[Gynecologic Oncology Group]]></category>
		<category><![CDATA[intraperitoneal chemotherapy]]></category>
		<category><![CDATA[Japanese Gynecological Oncology Group]]></category>
		<category><![CDATA[metronomic chemotherapy]]></category>
		<category><![CDATA[Michael A. Bookman M.D.]]></category>
		<category><![CDATA[NCI]]></category>
		<category><![CDATA[NCI Division of Cancer Treatment & Diagnosis]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[Ronald Alvarez M.D.]]></category>
		<category><![CDATA[Taxol]]></category>
		<category><![CDATA[Ted Trimble M.D. M.P.H.]]></category>
		<category><![CDATA[The Lancet]]></category>
		<category><![CDATA[Univ. of Alabama Birmingham]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3131</guid>
		<description><![CDATA[
Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers reported last week. In a large phase III clinical trial, women who received carboplatin every 3 weeks and a reduced dose of paclitaxel (Taxol®) once a week for 3 weeks [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3131&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/09/24/modified-chemo-regime-increases-survival-in-advanced-ovarian-cancer-patients-but-adds-toxicity/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/09/trimble.jpg" medium="image">
			<media:title type="html">Edward L. Trimble, MD, MPH</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/09/bookman.jpg" medium="image">
			<media:title type="html">Michael A. Bookman, M.D.</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/09/alvarez.jpg" medium="image">
			<media:title type="html">Ronald Alverz</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA Clears Vermillion&#8217;s &#8220;OVA1&#8243; Test To Determine Likelihood of Ovarian Cancer In Women With Pelvic Mass</title>
		<link>http://healthinfoispower.wordpress.com/2009/09/15/fda-clears-vermillions-ova1-test-to-determine-likelihood-of-ovarian-cancer-in-women-with-pelvic-mass/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/09/15/fda-clears-vermillions-ova1-test-to-determine-likelihood-of-ovarian-cancer-in-women-with-pelvic-mass/#comments</comments>
		<pubDate>Wed, 16 Sep 2009 04:45:59 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Biomarker]]></category>
		<category><![CDATA[Diagnosis & Treatment]]></category>
		<category><![CDATA[Molecular Diagnostics]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Apolipoprotein A-1]]></category>
		<category><![CDATA[beta2-microglobulin]]></category>
		<category><![CDATA[CA125]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Frederick R. Ueland M.D.]]></category>
		<category><![CDATA[Gail S. Paige]]></category>
		<category><![CDATA[gynecologic oncologists]]></category>
		<category><![CDATA[in vitro diagnostic multivariate index assays]]></category>
		<category><![CDATA[IVDMIA]]></category>
		<category><![CDATA[Jon R. Cohen M.D.]]></category>
		<category><![CDATA[Markey Cancer Ctr]]></category>
		<category><![CDATA[National Ovarian Cancer Awareness Month]]></category>
		<category><![CDATA[OVA1]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[Ovarian Tumor Triage Test]]></category>
		<category><![CDATA[pelvic mass]]></category>
		<category><![CDATA[Quest Diagnostics]]></category>
		<category><![CDATA[Society of Gynecologic Oncologists]]></category>
		<category><![CDATA[transferrin]]></category>
		<category><![CDATA[transthyretin]]></category>
		<category><![CDATA[Univ. of Kentucky]]></category>
		<category><![CDATA[Vermillion Inc.]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3101</guid>
		<description><![CDATA[
The U.S. Food and Drug Administration cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.

First Lab Test That Can Indicate Ovarian Cancer Prior [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3101&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/09/15/fda-clears-vermillions-ova1-test-to-determine-likelihood-of-ovarian-cancer-in-women-with-pelvic-mass/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2008/08/fdalogo3.jpg" medium="image">
			<media:title type="html">FDA Logo</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/09/ueland.jpg" medium="image">
			<media:title type="html">Frederick R. Ueland, M.D.</media:title>
		</media:content>
	</item>
		<item>
		<title>Barack Obama Proclaims September 2009 As National Ovarian Cancer Awareness Month</title>
		<link>http://healthinfoispower.wordpress.com/2009/09/01/barack-obama-proclaims-september-2009-as-national-ovarian-cancer-awareness-month/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/09/01/barack-obama-proclaims-september-2009-as-national-ovarian-cancer-awareness-month/#comments</comments>
		<pubDate>Wed, 02 Sep 2009 01:06:22 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[Fund-Rasing Event]]></category>
		<category><![CDATA[Legislation]]></category>
		<category><![CDATA[early warning signs & symptoms]]></category>
		<category><![CDATA[National Ovarian Cancer Awareness Month]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[President Barack Obama]]></category>
		<category><![CDATA[September 2009]]></category>
		<category><![CDATA[The White House]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=3092</guid>
		<description><![CDATA[
Yesterday,  U.S. President Barack Obama designated September 2009 as National Ovarian Cancer Awareness Month.  National Ovarian Cancer Awareness Month helps educate women and men about the importance of knowing the early warning signs and symptoms of the disease, scheduling routine doctor visits, and continuing robust scientific research.

Yesterday,  U.S. President Barack Obama designated September [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=3092&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/09/01/barack-obama-proclaims-september-2009-as-national-ovarian-cancer-awareness-month/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/09/whitehouseseal.jpg" medium="image">
			<media:title type="html">White House Seal</media:title>
		</media:content>
	</item>
		<item>
		<title>To Fight Cancer, Know The Enemy</title>
		<link>http://healthinfoispower.wordpress.com/2009/08/24/to-fight-cancer-know-the-enemy/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/08/24/to-fight-cancer-know-the-enemy/#comments</comments>
		<pubDate>Mon, 24 Aug 2009 16:55:12 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[General]]></category>
		<category><![CDATA[Opinions]]></category>
		<category><![CDATA[Attack by Stratagem]]></category>
		<category><![CDATA[Cold Spring Harbor Laboratory]]></category>
		<category><![CDATA[DNA double helix structure]]></category>
		<category><![CDATA[enzymes]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[HER-2]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Human Genome Project]]></category>
		<category><![CDATA[James D. Watson]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[National Institutes of Health]]></category>
		<category><![CDATA[NCI]]></category>
		<category><![CDATA[Nobel Prize for Physiology or Medicine]]></category>
		<category><![CDATA[Otto Warburg]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[President Barack Obama]]></category>
		<category><![CDATA[President Nixon]]></category>
		<category><![CDATA[signaling pathways]]></category>
		<category><![CDATA[Sun Tzu]]></category>
		<category><![CDATA[The Art of War]]></category>
		<category><![CDATA[The New York Times]]></category>
		<category><![CDATA[To Fight Cancer Know the Enemy]]></category>
		<category><![CDATA[transporter protein]]></category>
		<category><![CDATA[venture capital]]></category>
		<category><![CDATA[War On Cancer]]></category>
		<category><![CDATA[White House]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=2923</guid>
		<description><![CDATA[
An Op-Ed entitled &#8220;To Fight Cancer, Know the Enemy&#8221; was published in The New York Times on August 6, 2009.  The author of the Op-Ed was James D. Watson, Ph.D.   James Watson co-discovered the DNA double helix structure; a discovery for which he received the 1962 Nobel Prize for Physiology or Medicine. In the [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=2923&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/08/24/to-fight-cancer-know-the-enemy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/watson-james.jpg?w=283" medium="image">
			<media:title type="html">James D. Watson</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/sun-tzu.jpg?w=199" medium="image">
			<media:title type="html">Sun Tzu</media:title>
		</media:content>
	</item>
		<item>
		<title>UA Research Team Designing Holographic Imaging System For Ovarian Cancer</title>
		<link>http://healthinfoispower.wordpress.com/2009/08/21/ua-research-team-designing-holographic-imaging-system-for-ovarian-cancer/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/08/21/ua-research-team-designing-holographic-imaging-system-for-ovarian-cancer/#comments</comments>
		<pubDate>Sat, 22 Aug 2009 02:26:23 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Discoveries]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[Genetics]]></category>
		<category><![CDATA[BIO5 Institute]]></category>
		<category><![CDATA[BRCA gene mutations]]></category>
		<category><![CDATA[BRCA1]]></category>
		<category><![CDATA[BRCA2]]></category>
		<category><![CDATA[fluorescence spectroscopy]]></category>
		<category><![CDATA[hologram]]></category>
		<category><![CDATA[Jennifer Barton]]></category>
		<category><![CDATA[Kenneth D. Hatch]]></category>
		<category><![CDATA[laparoscopic surgery]]></category>
		<category><![CDATA[Marek Romanowski]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[Raymond Kostuk]]></category>
		<category><![CDATA[Society of Pelvic Surgeons]]></category>
		<category><![CDATA[Univ. of Arizona]]></category>
		<category><![CDATA[Univ. of Arizona College of Medicine]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=2921</guid>
		<description><![CDATA[
University of Arizona  researchers Jennifer Barton and Ray Kostuk have received a five-year, $2.4 million grant from the National Institutes of Health to build the instrument that they hope will one day be used to monitor women at high risk for ovarian cancer.

Two University of Arizona [UA] researchers have formed a research team to [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=2921&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/08/21/ua-research-team-designing-holographic-imaging-system-for-ovarian-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/hologramhumanovary.jpg" medium="image">
			<media:title type="html">Hologram of Human Ovary</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/hologramonion.jpg" medium="image">
			<media:title type="html">Hologram of An Orange</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/bartonjennifer.jpeg" medium="image">
			<media:title type="html">Jennifer Barton, UA</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/kostukray.jpg" medium="image">
			<media:title type="html">Ray Kostuk</media:title>
		</media:content>
	</item>
		<item>
		<title>NCCN Updates Infection Guidelines To Include Information About H1N1 Virus (Swine Flu)</title>
		<link>http://healthinfoispower.wordpress.com/2009/08/19/nccn-updates-infection-guidelines-to-include-information-about-h1n1-virus-swine-flu/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/08/19/nccn-updates-infection-guidelines-to-include-information-about-h1n1-virus-swine-flu/#comments</comments>
		<pubDate>Wed, 19 Aug 2009 21:08:06 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Coping]]></category>
		<category><![CDATA[Medical Guidelines]]></category>
		<category><![CDATA[Doribax]]></category>
		<category><![CDATA[doripenem]]></category>
		<category><![CDATA[Gilead Sciences Inc.]]></category>
		<category><![CDATA[H1N1 virus]]></category>
		<category><![CDATA[national comprehensive cancer network]]></category>
		<category><![CDATA[NCCN]]></category>
		<category><![CDATA[NCCN Clinical Practice Guidelines in Oncology]]></category>
		<category><![CDATA[NCCN Member Institutions]]></category>
		<category><![CDATA[Ortho-McNeil-Janssen Pharma Inc.]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[Prevention & Treatment of Cancer-Related Infections]]></category>
		<category><![CDATA[Swine Flu]]></category>
		<category><![CDATA[tenofovir disoproxil fumarate]]></category>
		<category><![CDATA[Viread]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=2919</guid>
		<description><![CDATA[
NCCN [National Comprehensive Cancer Network] recently updated the NCCN Clinical Practice Guidelines in Oncology™ for the Prevention and Treatment of Cancer-Related Infections to include information about the H1N1 virus, also known as “swine flu”. The NCCN Guidelines provide specific recommendations on the prevention, diagnosis, and treatment of the major common and opportunistic infections that afflict [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=2919&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/08/19/nccn-updates-infection-guidelines-to-include-information-about-h1n1-virus-swine-flu/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/nccn1.gif" medium="image">
			<media:title type="html">National Comprehensive Cancer Network logo</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/swineflucdc.jpg?w=254" medium="image">
			<media:title type="html">CDC Swine Flu picture</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA Issues Final Rules to Help Patients Gain Access to Investigational Drugs</title>
		<link>http://healthinfoispower.wordpress.com/2009/08/14/fda-issues-final-rules-to-help-patients-gain-access-to-investigational-drugs/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/08/14/fda-issues-final-rules-to-help-patients-gain-access-to-investigational-drugs/#comments</comments>
		<pubDate>Sat, 15 Aug 2009 04:34:59 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Federal Legislation]]></category>
		<category><![CDATA[Insurance]]></category>
		<category><![CDATA[Pipeline Drugs]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[Center For Drug Evaluation & Research]]></category>
		<category><![CDATA[compassionate use treatment]]></category>
		<category><![CDATA[expanded access]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[investigational drugs]]></category>
		<category><![CDATA[Investigational New Drug Application]]></category>
		<category><![CDATA[Janet Woodcock M.D.]]></category>
		<category><![CDATA[Margaret A. Hamburg M.D.]]></category>
		<category><![CDATA[ovarian cancer]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=2993</guid>
		<description><![CDATA[
The U.S. Food and Drug Administration (FDA) published two rules [on August 12, 2009] &#8230;that seek to clarify the methods available to seriously ill patients interested in gaining access to investigational drugs and biologics when they are not eligible to participate in a clinical trial and don’t have other satisfactory treatment options.

The U.S. Food and [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=2993&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/08/14/fda-issues-final-rules-to-help-patients-gain-access-to-investigational-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2008/08/fdalogo3.jpg" medium="image">
			<media:title type="html">FDA logo</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/hamburg_official_portrait.jpg?w=240" medium="image">
			<media:title type="html">Margaret Hamburg M.D., Comissioner of Food &#38; Drugs</media:title>
		</media:content>
	</item>
		<item>
		<title>Women Often Opt to Surgically Remove Their Breasts, Ovaries to Reduce Cancer Risk</title>
		<link>http://healthinfoispower.wordpress.com/2009/08/14/women-often-opt-to-surgically-remove-their-breasts-ovaries-to-reduce-cancer-risk/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/08/14/women-often-opt-to-surgically-remove-their-breasts-ovaries-to-reduce-cancer-risk/#comments</comments>
		<pubDate>Fri, 14 Aug 2009 21:45:23 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Genetic Testing]]></category>
		<category><![CDATA[Genetics]]></category>
		<category><![CDATA[Medical Study Results]]></category>
		<category><![CDATA[Ovarian Cancer Risk]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[American Association For Cancer Research]]></category>
		<category><![CDATA[BRCA gene mutations]]></category>
		<category><![CDATA[BRCA1]]></category>
		<category><![CDATA[BRCA2]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[Cancer Epidemiology Biomarkers Prevention journal]]></category>
		<category><![CDATA[Claudine Isaacs M.D.]]></category>
		<category><![CDATA[Fisher Center For Familial Cancer Research]]></category>
		<category><![CDATA[Gareth Evans M.D.]]></category>
		<category><![CDATA[Genesis Prevention Center]]></category>
		<category><![CDATA[genetic couseling]]></category>
		<category><![CDATA[Georgetown University]]></category>
		<category><![CDATA[hereditary breast and ovarian cancer]]></category>
		<category><![CDATA[Lombardi Comprehensive Cancer Center]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[risk-reducing mastectomy]]></category>
		<category><![CDATA[risk-reducing salpingo oophorectomy]]></category>
		<category><![CDATA[Univ. Hospital of South Manchester]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=2917</guid>
		<description><![CDATA[
Many women at high risk for breast or ovarian cancer are choosing to undergo surgery as a precautionary measure to decrease their cancer risk, according to a report in Cancer Epidemiology, Biomarkers &#38; Prevention, a journal of the American Association for Cancer Research.

PHILADELPHIA &#8211; Many women at high risk for breast or ovarian cancer are [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=2917&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/08/14/women-often-opt-to-surgically-remove-their-breasts-ovaries-to-reduce-cancer-risk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/gareth.jpg?w=253" medium="image">
			<media:title type="html">Gareth Evans M.D.</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/claudine_2009_july_photo_credit_phil_humnicky_georgetown.jpg?w=199" medium="image">
			<media:title type="html">Claudine_2009_July_(photo_credit_Phil_Humnicky,_Georgetown)</media:title>
		</media:content>
	</item>
		<item>
		<title>Young Early-Stage Ovarian Cancer Patients Can Preserve Fertility</title>
		<link>http://healthinfoispower.wordpress.com/2009/08/11/young-early-stage-ovarian-cancer-patients-can-preserve-fertility/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/08/11/young-early-stage-ovarian-cancer-patients-can-preserve-fertility/#comments</comments>
		<pubDate>Tue, 11 Aug 2009 21:50:54 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Fertility]]></category>
		<category><![CDATA[Medical Study Results]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[American Cancer Society]]></category>
		<category><![CDATA[board-certified]]></category>
		<category><![CDATA[CANCER journal]]></category>
		<category><![CDATA[clear cell adenocarcinoma]]></category>
		<category><![CDATA[Columbia Univ. College of Physicians & Surgeons]]></category>
		<category><![CDATA[fertility preservation]]></category>
		<category><![CDATA[gynecologic oncologists]]></category>
		<category><![CDATA[hysterectomy]]></category>
		<category><![CDATA[Jason Wright M.D.]]></category>
		<category><![CDATA[National Cancer Institute]]></category>
		<category><![CDATA[oophorectomy]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[SEER cancer registries]]></category>
		<category><![CDATA[SEER data]]></category>
		<category><![CDATA[Surveillance Epidemiology & End Results]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=2915</guid>
		<description><![CDATA[
A new study finds that young women with early-stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease. The study is published in the September 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

A new study [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=2915&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/08/11/young-early-stage-ovarian-cancer-patients-can-preserve-fertility/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/fertility.jpg?w=300" medium="image">
			<media:title type="html">fertility</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/wrightjason.jpg" medium="image">
			<media:title type="html">Jason Wright</media:title>
		</media:content>
	</item>
		<item>
		<title>Novel Targeted Gene Therapies Use Diphtheria Toxin To Fight Ovarian Cancer; One Clinical Trial Underway</title>
		<link>http://healthinfoispower.wordpress.com/2009/08/10/novel-targeted-gene-therapies-use-diphtheria-toxin-to-fight-ovarian-cancer-future-clinical-trials-anticipated/</link>
		<comments>http://healthinfoispower.wordpress.com/2009/08/10/novel-targeted-gene-therapies-use-diphtheria-toxin-to-fight-ovarian-cancer-future-clinical-trials-anticipated/#comments</comments>
		<pubDate>Mon, 10 Aug 2009 19:16:33 +0000</pubDate>
		<dc:creator>Paul Cacciatore</dc:creator>
				<category><![CDATA[Biological Therapies]]></category>
		<category><![CDATA[Gene Therapies]]></category>
		<category><![CDATA[Genetics]]></category>
		<category><![CDATA[Medical Study Results]]></category>
		<category><![CDATA[Novel Therapies]]></category>
		<category><![CDATA[nanotechnology]]></category>
		<category><![CDATA[Abramson Cancer Ctr.]]></category>
		<category><![CDATA[Ami Fishman M.D.]]></category>
		<category><![CDATA[ascites]]></category>
		<category><![CDATA[Aya Mizrahi]]></category>
		<category><![CDATA[BC-819]]></category>
		<category><![CDATA[BioCancell Therapeutics]]></category>
		<category><![CDATA[Cancer Research journal]]></category>
		<category><![CDATA[Cecelia Boardman M.D.]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Corynebacterium diphtheriae]]></category>
		<category><![CDATA[Daniel Anderson Ph.D.]]></category>
		<category><![CDATA[David Edelman M.D.]]></category>
		<category><![CDATA[David H. Koch Institute for Integrative Cancer Research]]></category>
		<category><![CDATA[Depart. of Defense]]></category>
		<category><![CDATA[diphtheria toxin]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[DT-A]]></category>
		<category><![CDATA[DTA-H19]]></category>
		<category><![CDATA[Edith Wolfson Medical Center]]></category>
		<category><![CDATA[gene expression]]></category>
		<category><![CDATA[gene therapy]]></category>
		<category><![CDATA[George Coukos M.D. Ph.D.]]></category>
		<category><![CDATA[Gregory Zugates Ph.D.]]></category>
		<category><![CDATA[H19 gene]]></category>
		<category><![CDATA[Hadassah University Hospital]]></category>
		<category><![CDATA[HE4 gene]]></category>
		<category><![CDATA[Janet Sawicki Ph.D.]]></category>
		<category><![CDATA[Jordan Green Ph.D.]]></category>
		<category><![CDATA[Journal of Translational Medicine]]></category>
		<category><![CDATA[Kaleidoscope of Hope Foundation]]></category>
		<category><![CDATA[Lankenau Institute of Med. Research]]></category>
		<category><![CDATA[Massachusetts Inst. of Tech.]]></category>
		<category><![CDATA[Massey Cancer Center]]></category>
		<category><![CDATA[Meir Hospital]]></category>
		<category><![CDATA[mesothelin]]></category>
		<category><![CDATA[MSLN gene]]></category>
		<category><![CDATA[nanoparticle]]></category>
		<category><![CDATA[Naushad Hossain]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[polymers]]></category>
		<category><![CDATA[RNA]]></category>
		<category><![CDATA[Robert Langer]]></category>
		<category><![CDATA[Sandy Rollman Foundation]]></category>
		<category><![CDATA[Tally Levy M.D.]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<category><![CDATA[Teal Ribbon Ovarian Cancer Foundation]]></category>
		<category><![CDATA[The Hebrew University of Jerusalem]]></category>
		<category><![CDATA[vector]]></category>
		<category><![CDATA[WFDC2 gene]]></category>

		<guid isPermaLink="false">http://healthinfoispower.wordpress.com/?p=2744</guid>
		<description><![CDATA[
Two separate  research teams reported promising results last  week based upon  preclinical studies involving the  use of  diphtheria toxin to fight ovarian cancer. &#8230;  A targeted gene therapy was utilized in both studies, wherein a gene fragment capable of producing diptheria toxin was combined with a nanoparticle which was [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthinfoispower.wordpress.com&blog=3013851&post=2744&subd=healthinfoispower&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthinfoispower.wordpress.com/2009/08/10/novel-targeted-gene-therapies-use-diphtheria-toxin-to-fight-ovarian-cancer-future-clinical-trials-anticipated/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/b0ebfd3d89f30da315e588fc8a1a0a06?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">paulc</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/anderson1.jpg" medium="image">
			<media:title type="html">Daniel Anderson, Ph.D.</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/langerrobert.jpg" medium="image">
			<media:title type="html">Robert S. Lander, David H. Koch Institute for Integrative Cancer Research Professor</media:title>
		</media:content>

		<media:content url="http://healthinfoispower.files.wordpress.com/2009/08/sawicki.jpg" medium="image">
			<media:title type="html">Janet Sawicki, Ph.D., Prof., Lankenau Institute of Medical Research</media:title>
		</media:content>
	</item>
	</channel>
</rss>